Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice

Neuroscience Letters

Volumn 322, Issue 1, 2002, Pages 13-16

  Xu, Kui ^a   Xu, Yue Hang ^b   Chen, Jiang Fan ^a   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A2A adenosine receptor; Dopamine; Dopamine transporter; Locomotion; Neuroprotection; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; CAFFEINE; DOPAMINE TRANSPORTER; ISTRADEFYLLINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERANCE; LOCOMOTION; LONG TERM EXPOSURE; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STIMULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BINDING SITES; CAFFEINE; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; MALE; MAZINDOL; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEOSTRIATUM; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARKINSONIAN DISORDERS; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; TRITIUM;

EID: 0037192439     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(02)00069-1     Document Type: Article

References (20)

1. Prospective study of caffeine intake and risk of Parkinson's disease in men and women
2. Smoking, alcohol, and coffee consumption preceding Parkinson's disease. A case-control study
3. 2A adenosine receptor inactivation in a model of Parkinson's disease
4. Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation
5. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors
6. Parkinson's disease and CYP1A2 activity
7. Adenosine actions and adenosine receptors after 1 week treatment with caffeine
8. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use
9. Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX
10. Lack of tolerance to motor effects of a selective adenosine A2A receptor antagonist
11. Role of adenosine receptors in caffeine tolerance
12. Adenosine receptor ligands: Differences with acute versus chronic treatment
13. Effect of long term caffeine treatment on A1 and A2 adenosine receptor binding and on mRNA levels in rat brain
14. Caffeine treatment and withdrawal in mice: Relationships between dosage, concentrations, locomotor activity and A1 adenosine receptor binding
15. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats
16. Association of coffee and caffeine intake with the risk of Parkinson's disease
17. Adenosine A2 receptor-mediated excitatory actions on the nervous system
18. Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens
19. The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions
20. Heterocyclic amine mixture carcinogenesis and its enhancement by caffeine in F344 rats